Bridging the Synthetic and Biopolymer Worlds with Peptide-Drug Conjugates

Bridging the Synthetic and Biopolymer Worlds

6. Piacentini, M., and Colizzi, V. (1999). Immunol. Today 3, 130–134. 11. Schuppan, D., and Hahn, E.G. (2002). Science 297, 2218–2220. 12. Griffin, M., Casadio, R., and Bergamini, C.M. (2002). Biochem. 7. Molberg, O., Mcadam, S.N., Korner, R., Quarsten, H., Kristiansen, C., Madsen, L., Fugger, L., Scott, H., Noren, O., RoepsJ. 368, 377–396. 13. De Laurenzi, V., and Melino, G. (2001). Mol. Cell....

Bridging disulfides for stable and defined antibody drug conjugates.

To improve both the homogeneity and the stability of ADCs, we have developed site-specific drug-conjugating reagents that covalently rebridge reduced disulfide bonds. The new reagents comprise a drug, a linker, and a bis-reactive conjugating moiety that is capable of undergoing reaction with both sulfur atoms derived from a reduced disulfide bond in antibodies and antibody fragments. A disulfid...

NGR-peptide−drug conjugates with dual targeting properties

Peptides containing the asparagine-glycine-arginine (NGR) motif are recognized by CD13/aminopeptidase N (APN) receptor isoforms that are selectively overexpressed in tumor neovasculature. Spontaneous decomposition of NGR peptides can result in isoAsp derivatives, which are recognized by RGD-binding integrins that are essential for tumor metastasis. Peptides binding to CD13 and RGD-binding integ...

Synthesis and in vitro antitumor effect of peptide - drug conjugates

Synthetic Animals in Synthetic Worlds

Abstract This paper provides an overview of various research e orts that aim at designing adaptive animats i e synthetic animals able to survive in synthetic worlds The control architectures of these animats are either programmed by a human designer or more or less automatically determined by means of nature mimicking processes such as learning evolution and develop ment The paper concludes wit...